ArticleClinical rheumatology2007
Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients.
Article in Clinical rheumatology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Circulating Amyloid and Misfolded Biomarkers in Early Myocardial Injury: A Systematic Review and Epistemic Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- The potential role of serum amyloid A as biomarker of rheumatic diseases: a systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Clinical rheumatology · 2020Pooled it
- Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression.Scientific reports · 2017Pooled it
- Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis.Inflammation · 2014Pooled it
- Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study.Aging and disease · 2016Article
- Article
- Association between serum total antioxidant status and flow-mediated dilation in patients with systemic lupus erythematosus: an observational study.Anatolian journal of cardiology · 2015Observational
- Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases).Frontiers in immunology · 2014Review
- Cardiovascular involvement in autoimmune diseases.BioMed research international · 2014Review
- High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus.Arthritis care & research · 2013Article
- The correlation between the cardio-ankle vascular index (CAVI) and serum amyloid A in asymptomatic Japanese subjects.Heart and vessels · 2012Article
- Therapeutic options for premature coronary artery disease.Current treatment options in cardiovascular medicine · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is associated with severe and premature cardiovascular disease, which cannot be explained by traditional risk factors alone. This study aims to investigate novel cardiovascular risk factors and cardiac event predictors in inactive SLE female patients who do not have any major cardiovascular risk factors. Twenty-five inactive (SLE disease activity index score <4) SLE female patients and 22 healthy control women were studied. SLE patients with a history of diabetes mellitus, hypertension, hyperlipidemia, smoking, or coronary artery disease (CAD) were excluded. Venous blood samples were analyzed for lipid subfractions and novel cardiovascular risk factors such as lipoprotein (a), homocysteine, fibrinogen, high-sensitivity C-reactive protein (hs-CRP), and serum amyloid A (SAA) levels. Endothelial dysfunction was assessed by flow-mediated dilatation (FMD) from the brachial artery at baseline and during reactive hyperemia. SLE patients and controls were similar in terms of age (40+/-10 years vs 38+/-10 years, p = NS). No significant difference was found between the groups regarding family history of premature CAD, blood pressure, body mass index, lipoprotein (a), homocysteine, fibrinogen, SAA, apoprotein A-1 and B levels. Compared with the controls, SLE patients had higher levels of hs-CRP [median (range): 1.82 (0.02-0.98) vs 0.68 (0.02-0.35), p=0.04]. FMD was lower in SLE patients than controls (7.1+/-2.1 vs 11.4+/-1.2%, p<0.001). Increased levels of hs-CRP and decreased FMD were found in inactive SLE patients. Increased hs-CRP levels may reflect ongoing low-grade inflammation that could be a cause of impaired FMD in SLE patients. These findings suggest that SLE patients without traditional major cardiovascular risk factors may have increased risk of cardiovascular disease and future cardiac events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.